| 2010 Jul 21 DRG® offers three new Elisa kits, based on the sandwich principle, for measurement of active Renin, Hepcidin, and PLGF tests as below. | ||||||||||||||||||||||||
|
DRG® Renin ELISA Renin measurement can be helpful in diagnosis and treatment of certain types of hypertension. Renin, which exists in both active and inactive forms, is a key factor in the regulation of arterial pressure and hydrosodic metabolism. While inactive Renin can account for up to 90% of the total Renin in circulation, it is the active Renin that cleaves angiotensionogen into angiotensin I, which ultimately leads to the production of angiotensin II - more active Renin (http://www.labmedica.com/?option=com_article&Itemid=294730651&cat=Lab+Technology&Custom%20Field%2012&end=%20). The DRG® Active Renin ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle.
DRG® Hepcidin Test Hepcidin is a peptide hormone secreted by the liver in response to iron loading and inflammation. Increased Hepcidin concentrations lead to decreased iron absorption. By contrast, a decreased Hepcidin state will cause increase iron release from the enterocyte and macrophages. It is thought that Hepcidin controls plasma iron levels by regulating the absorption of iron from the intestine and the release of iron in the macrophage and hepatocyte. The DRG® Hepcidin ELISA Kit is a solid phase enzyme-linked immunosorbent assay (ELISA), based on the principle of competitive binding.
DRG® Placental Growth Factor Test In 5-8% of all pregnancies, Preeclampsia causes an increase in the mother's blood pressure, excretion of protein, and edemas - in the majority of cases, this occurs in the last trimester of pregnancy. These clinical conditions, together termed Preeclampsia, are a risk for mother and child which make it necessary to induce premature birth. Studies about Preeclampsia have shown that important growth factores are affected which causes malnutrition of placenta and fetus.The PLGF ELISA allows for early detection of the developmental risk factors of Preeclampsia and is therefore an important new tool in the health protection of mother and child.
|
||||||||||||||||||||||||
| 2010 Jun 30 The iron-regulatory peptide hepcidin is upregulated in the ischemic and in the remote myocardium after myocardial infarction. | ||||||||||||||||||||||||
|
Abstract by Simonis G1, Mueller K, Schwarz P, Wiedemann S, Adler G, Strasser RH, Kulaksiz H. Department of Medicine and Cardiology, Dresden University of Technology, Heart Center, D-01307 Dresden, Germany. AbstractRecent evidence suggests that iron metabolism contributes to the ischemic damage after myocardial infarction. Hepcidin, a recently discovered peptide hormone, regulates iron uptake and metabolism, protecting the body from iron overload. In this study we analyzed the regulation of hepcidin in the heart and blood of rats after myocardial infarction. To induce a myocardial infarction in the rats, left anterior descending coronary artery ligation was performed. After 1-24h, biopsies from the ischemic and the non-ischemic myocardium were taken. In these biopsies, the mRNA levels and the protein expression of hepcidin were analyzed by quantitative RT-PCR and immunoblot analysis, respectively. In parallel, the serum levels of prohepcidin were measured by ELISA. Six hours after myocardial infarction, the hepcidin mRNA expression was temporally upregulated in the ischemic and in the non-ischemic myocardium. The upregulation was specific for hepcidin, since other iron-related genes (hemojuvelin, IREG-1) remained unchanged. Furthermore, the alteration of the hepcidin protein expression in the ischemic area was connected to the level of hepcidin in the serum of the infarcted rats, where hepcidin also raised up. Angiotensin receptor blockade with candesartan did not influence the mRNA regulation of hepcidin. Together, these data show a particular upregulation of the iron-regulatory peptide hepcidin in the ischemic and the non-ischemic myocardium after myocardial infarction. It is speculated that upregulation of hepcidin may reduce iron toxicity and thus infarct size expansion in an infarcted heart. Copyright © 2010 Elsevier Inc. All rights reserved.
|
||||||||||||||||||||||||
| 2009 Sep 06 Development and Validation of an ELISA for the detection of Fasciola hepatica in human patient sera | ||||||||||||||||||||||||
|
Abstract by Tatiana Wehde1, Alfred Janetzko1 1 DRG Instruments GmbH, Frauenbergstr. 18, 35039 Marburg, Germany Introduction The common liver fluke (Fasciola hepatica) is a worldwide distributed parasitic flatworm with a complex life cycle. It infects cattle and sheep, but occasionally also humans after consumption of metacercariae-contaminated fruit or herbs. Watercress, for example, is a common source of infection both for humans and animals. Ingested metacercariae (immature flukes) migrate to the liver and gallbladder, where mature liver flukes develop (Figure 1). Pathological symptoms of a liver fluke infection in humans range from asymptomatic to severe abdominal pain and fever, making a diagnosis very difficult. In many cases an infection with Fasciola hepatica is not recognized. The most widely used form of diagnosis of a Fascioliasis is the observation of Fasciola hepatica eggs in stool. However, eggs are only observed in later stages of infection and may easily be missed. To overcome these disadvantages we developed a qualitative microtiter strip based ELISA for the detection of IgG class antibodies against Fasciola hepatica in human serum. Materials and Methods Assay Design: The DRG® FASCIOLA HEPATICA IgG (human) ELISA is a solid phase enzyme immunoassay based on the sandwich principle. The 96 well breakable microtiterplate is coated with antigen from adult Fasciola hepatica. In a first incubation step Fasciola hepatica-specific IgG antibodies from diluted patient sera and ready to use controls bind to the immobilized antigen. After washing away unbound material, horseradish peroxidase conjugated anti-human IgG antibodies (conjugate) form a sandwich complex in the presence of anti-Fasiola Hepatica IgG during the second incubation step (Figure 2). After a second washing step immune complexes are detected colorimetrically by incubation with TMB substrate. The intensity of the developing color is directly proportional to the amount of Fasciola hepatica-specific IgG antibody in the patient specimen. Absorbance at 450 nm is read using an ELISA microtiter plate reader. The total incubation time of the ELISA is 105 minutes. The exact protocol of the assay is given here. Patient Samples: Pathological patient samples were remnants from routine analysis obtained from several russian clinical centers. Diagnosis of Fascioliasis and other parasite infections was based on traditional methods like microscopy. Healthy patient samples were remnants from routine analysis obtained from several european clinical centers.
Figure 1. Adult Fasciola hepatica (Liver Fluke)
Results Precision and stability Using control sera containing different amounts of IgGs against Fasciola Hepatica we oberserved Intra-Assay Variations between 2.8% and 2.9 %. In Inter-Assay studies precisions of 1.9 to 2.1 % were observed for the Fasciola Hepatica IgG ELISA. The ELISA was found to be stable for at least one year. Sensitivity and Specificity: In initial studies we tested both sera from healthy patients (N=235) and confirmed Fasciola Hepatica infected patients (N= 13). A patient sample is considered positive, if: OD patient > 1.1X OD cut-off control. A patient sample is considered negative, if: OD patient < 0.9X OD cut-off control. The range between 0.9X OD cut-off control and 1.1X OD cut-off control is considered grey zone. All healthy patients were tested negative (Diagnostic specificity: 100%). When we tested 13 patients infected with Fasciola Hepatica we got positive results in all 13 cases (Diagnostic sensitivity: 100%). To further analyze specificity we assayed a panel of patients infected with various parasites (Total Number of patients: 69). The results are summarized in Figure 4. Also sera of patients afflicted with other parasites did not react positive with the ELISA.
Figure 2: Specificity and sensitivity of Fasciola Hepatica ELISA.
Conclusion Fascioliasis in humans is a serious health problem in some rural areas worldwide. The DRG® FASCIOLA HEPATICA IgG (human) ELISA is a quick and simple method to detect a Fascioliasis in serum. Due to its high precision, sensitivity and specificity the ELISA is suitable to diagnose infection with Fasciola Hepatica earlier and less subjective as compared to visual stool analysis.
|
||||||||||||||||||||||||
| 2009 Aug 24 WORLD'S FIRST HEPCIDIN TESTING KIT NOW AVAILABLE ! | ||||||||||||||||||||||||
|
Test kit helps quickly diagnose iron disorders, including hemochromatosis and anemia. MOUNTAINSIDE, NEW JERSEY (Monday, August 24, 2009) - Today, DRG International, Inc., a leading international medical diagnostic company, has released the first and only diagnostic kit to measure the hormone Hepcidin. In recent years, scientists discovered that Hepcidin helps regulate the amount of iron in humans. Unbalanced iron level can lead to many common medical conditions including anemia and iron overload diseases, or it can occur in chronic kidney disease, inflammation, or diabetes mellitus. The DRG® Hepcidin 25 (C-Terminal) ELISA Kit will be available to medical professionals worldwide, providing the first simple, fast and accurate method to test patient Hepcidin levels. The measurement results will offer more information to clinicians to help doctors diagnose and treat medical conditions including iron deficiency diseases, some of the most common diseases worldwide. "With many health problems related to Hepcidin, the research team at DRG® recognized the need to invent a testing kit, and put it in the hands of health professionals across the globe as soon as possible," stated Dr. Cyril E. Geacintov, Chairman of DRG International. "This kit provides accurate information, is user-friendly, and will help meet the rapidly growing worldwide demand for such a testing kit." The new ELISA Hepcidin kit was jointly developed by research teams in the United States and Germany, under the strict standards of DRG International. The Hepcidin ELISA kit is fully patented and available worldwide. The inventors of these patents are Dr. Hasan Kulaksiz, Dr. Alfred Janetzko, and Dr. Cyril E. Geacintov. For more information, please visit: www.drg-international.com.
|
||||||||||||||||||||||||
| 2009 Mar 5 New DRG® Connective Tissue Growth Factor (CTGF) Elisa | ||||||||||||||||||||||||
|
b) Kovalenko, E., F. Tacke, O.A. Gressner, H.W. Zimmermann, B. Lahme, A. Janetzko, T. Wiederholt, T. Berg, T. Müller, C. Trautwein, A.M. Gressner, and R. Weiskirchen. Validation of Connective Tissue Growth Factor (CTGF/CCN2) and Its Gene Polymorphisms as Non-Invasive Biomarkers for the Assessment of Liver Fibrosis. J. Viral Hepatitis (2008) DOI:10.1111/j.1365-2893.2009.01110.x.
|
||||||||||||||||||||||||
| 2009 Feb 19 Vitamin Assays added to the DRG® product lines offered for sale in China | ||||||||||||||||||||||||
|
|
||||||||||||||||||||||||
| 2008 Dec 8 HEPCIDIN: Second U.S. Patent is issued to DRG® for its diagnostic kit | ||||||||||||||||||||||||
|
Dr. Cyril Geacintov, President and CEO, DRG International, is pleased to announce that it has received U.S. Patent 7,411,048, issued August 12, 2008 , in addition to U.S. Patent 7,320,894 issued January 22, 2008. These patents are directed to diagnostic antibodies and diagnostic kits for the detection of mature hepcidin and prohepcidin. In the United States, these kits are for Research Use Only. These patents are part of a larger patent portfolio directed to the protection of DRG International's scientific and marketplace leadership in this field. DRG International is a leader in the development and manufacture of commercial diagnostic kits for the detection of various disease markers. DRG International is the sole supplier of commercially available kits for the detection of hepcidin, enabling a simple and widely practicable immunoassay (ELISA) to be used for direct measurement of hepcidin concentration in human fluids. The mature form of prohepcidin, hepcidin, is a major player in iron metabolism, and abnormal levels of hepcidin have been observed in various diseases including diabetes, chronic renal insufficiency and various anemias, and Hemochromatosis as an additional disease target. |
||||||||||||||||||||||||
| 2008 Jan 30 17α-hydroxy Progesterone (Salivary) test is cleared by the U.S. FDA | ||||||||||||||||||||||||
|
We are pleased to inform all DRG® customers interested in the DRG® Saliva tests, that the U.S. FDA has accepted the diagnostic and clinical data supplied by DRG® to clear the 17α-OH Progesterone Saliva kit (SLV-3140) for use in the USA and worldwide. With the addition of the 17α-OH Progesterone saliva kit, the menu of FDA-cleared salivary test kits developed and manufactured by DRG® has once again grown along with broad use of these products in a diagnostic setting. |
||||||||||||||||||||||||
| 2008 Jan 22 Hepcidin Patent Issued to DRG® | ||||||||||||||||||||||||
|
U.S. Patent No. 7,320,894 issued to DRG® on January 22, 2008 - The Patent describes the diagnostic method for diseases by screening for Hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor. Dr. Cyril Geacintov, President of DRG International, Inc. announced today that the extensive research and clinical efforts of the past several years have been recognized as an important contribution for the screening methods for Hepcidin, an important protein in the regulation of iron metabolism in the human body. The invention is based on research carried out by Dr. Kulaksiz at Heidelberg University and Dr. Stremmel at the same location, and Dr. Janetzko, Head of the R&D Department of the DRG® Subsidiary DRG Instruments in Marburg. |
||||||||||||||||||||||||
| 2008 Jan 09 Preeclampsia New Test Developed by DRG® | ||||||||||||||||||||||||
|
Preeclampsia is a disorder which only occurs during pregnancy and affects both the mother and the unborn baby in 5 to 8% of all pregnancies. The DRG® ELISA PLGF (Free Placental Growth Factor) kit has been tested extensively as a method to determine the occurrence of preeclampsia in pregnant women as described in the Clinical Chemistry and Laboratory Medicine publication, No. 11/2007, by Markus Schmidt et al. from the Department of Gynecology and Obstetrics at the University of Duisburg-Essen in Germany. Dr. Alfred Janetzko, Director of R&D at DRG® in Marburg, Germany, is a co-author of this paper. Preeclampsia is a major cause of maternal and perinatal mortality worldwide. It is a multi-systemic disorder affecting mother and child at the end of the second trimester of gestation (after week 15). The DRG® PLGF ELISA test kit, in combination with other circulating angiogenic factors, was shown to be a reliable system to assess the occurrence of preeclampsia in the 15th to 18th weeks and later in gestation in the second or third trimester of the pregnancy. The DRG® PLGF ELISA test showed a cut-off of 49 pg/ml as early as the 15th week of gestation. Early detection of preeclampsia is of the upmost importance. Dr. Schmidt stated, «The application of the DRG® ELISA kit makes it possible to start therapy at this early stage to avoid preeclampsia in the further gestation process.» The DRG® PLGF ELISA test kit requires only 25 microliters of the mother's serum to carry out the determinations based on the solid-phase sandwich principle.  PGLF measurements in 30 preeclamptic pregnant women. The reference curve was derived from 275 measurements in 64 healthy pregnant women (mean and 95% confidence interval). In comparing PLGF in preeclamptic and normal pregnancies, it was shown that preeclamptic pregnancies show a significantly lower serum concentration of PLGF as compared to the patient with a non-preeclamptic pregnancy. Data published in Clinical Chemistry and Laboratory Medicine, No. 11/2007, demonstrate that between the 15th and 18th week, all patients with clinical signs of preeclampsia have a PLGF expression of less than 100 pg/ml. During this period, all patients with non-preeclamptic pregnancy had an expression of PLGF greater than 100 pg/ml with a cut-off value of 49 pg/ml. The DRG® ELISA PLGF kit supplies “ready-to-use” reagents and can be carried out, including several incubation periods, in less than 2.5 hours. Preeclampsia and other hypertensive disorders of pregnancy are a leading global cause of maternal and infant illness and death. Early recognition of the occurrence of preeclampsia can be instrumental in preserving the life of both the baby and the mother by adequate and timely treatment and care. For more information on the DRG® PLGF ELISA and the determinations carried out, please request a copy of the publication entitled, “Altered Angiogenesis in Preeclampsia: Evaluation of a New Test System for Measuring Placental Growth Factor” by Markus Schmidt et al. Clin Chem Lab Med 2007; 45(11): 1504-1510 To place an order: Please contact the DRG® Customer Service Department or your local Distributor. In the United States, please call 908-233-2079. Please refer to kit number: EIA-4529. |
||||||||||||||||||||||||
| 2007 Aug 27 NEW CHROMagar VRE !!! DRG® launches new CHROMagar medium ! | ||||||||||||||||||||||||
|
DRG® is pleased to introduce the newest addition to its CHROMagar™ product line: CHROMagar™ VRE This medium is targeted to detect the Vancomycin Resistant Enterococcus faecalis and faecium and to differentiate them from the other bacteria. Why differentiate VRE.faecalis and VRE.faecium from the other species? Because, when these two strains acquire the resistance, they might transfer it to much more dangerous micro-organisms i.e. Staph.aureus, etc. Thus, to efficiently control the spread of these strains, one needs a fast and highly specific screening test. This is the goal achieved with the new CHROMagar™ VRE. For more details, please refer to the CHROMagar™ VRE product leaflet |
||||||||||||||||||||||||
| 2007 Mar 28 NEW DRG® Animal ELISAs - DRG® announces its newest line of Veterinary ELISAs ! | ||||||||||||||||||||||||
|
From farm animals and loving companion animals to laboratory animals important for life science research, DRG® veterinary products have proven to be vital in the evaluation of their well being. Canine Test Kit Products
Test also available as 20 Test Format. |
||||||||||||||||||||||||
| 2007 Mar 28 DRG® now offers a new line of unique qualitative ELISA-based test kits for rat and mouse virus detection ! | ||||||||||||||||||||||||
|
We are pleased to offer some new and unique qualitative ELISA-based test kits for rat and mouse virus detection for your research customers. These easy-to-use kits allow the research scientist to test rats and mice for common viruses. Early detection of these viral infections could avoid problems such as contamination of cultures, low ascites production, interference with experimental procedures, increased susceptibility to other infections, or death.
1) Laboratory Animal Virus Detection ELISA Kits (Murine Infectious Diseses)
We offer a range of EIA to detect for the viruses that typically can infect rats or mice and these offer the following attributes: Break away wells allow low-volume testing
2) Canine and Equine Virus Detection ELISA Kits
We offer a new range of ELISAs to detect different types of Borreliosis and Ehrlichia in dogs and horses, Rickettsia and Leishmania in dogs. Very convenient for smaller laboratories: we have the kits in a 20 well-kit version and in a 96-well-kit version.
3) Life Science Research EIA
Carefully crafted and manufactured to exacting standards, our ELISA based diagnostic tools yield highly valuable data in clinical studies regarding congestive heart disease, infectious diseases, arthritis and other inflammatory conditions. Our current product line consists of quantitative tests for dog, rat and human CRP.
|
||||||||||||||||||||||||
| 2007 Mar 23 DRG® introduces NEW Avian Influenza A ELISA Kit | ||||||||||||||||||||||||
|
Highly Pathogenic Avian Influenza (HPAI) has begun to re-appear in many Asian, Middle Eastern, and European countries in 2007!!: Afghanistan, China, Djibouti, Hong Kong, Hungary, Japan, Korea, Kuwait, Laos, Myanmar, Pakistan, Russia, Slovenia, Thailand, Turkey, United Kingdom, Vietnam (source: www.oie.int)
DRG® International now offers Influenza A Nucleoprotein Antigen Capture ELISA, a highly sensitive and specific ELISA for the detection of Influenza A nucleoprotein (NP) antigen, an internal viral protein that is highly conserved and expressed in all influenza A subtypes whether of human or veterinary origin, e.g., H1N1, H3N2, H5N1, H7N2, H9N2, etc. Detection of influenza A NP in complex, original sample material with high sensitivity and specificity permits the rapid identification of influenza A-positive specimens without the need to amplify highly pathogenic virus that might be present within a sample. The new assay is very simple to perform, contains only one wash step, and can be completed in less than 1.5 hr. Enzyme-linked Immunosorbent Assay Technology
High Sensitivity High Specificity Original Sample Capability Cost-effective High precision/low variability Lot-to-lot consistency For more information about the Influenza A Nucleoprotein Antigen Capture ELISA and other products, please contact: Mary Lou Delle Donne in the Customer Service Department of DRG® International, Inc., 908-233-2079 or via e-mail at: mdelledonne@drg-international.com |
||||||||||||||||||||||||
| 2007 Mar 01 NEW packaging size for small packs of CHROMagar™ dehydrated culture media | ||||||||||||||||||||||||
|
Effective March 1, 2007, DRG® will no longer offer the small packs of 4x250 ml CHROMagar™ media as CHROMagar™ will stop commercialization of the 4x250 ml packs and replace them with one unique bottle of 1000 ml. The only CHROMagar™ product that will continue to be produced in 4x250 ml/pack is the CHROMagar™ Listeria (Ref. No. LM850). Please note that the same Reference Nos. for the old 4x250 ml packs will be used for the new 1000 ml packs to simplify the change. Click on this link to view the updated CHROMagar™ price list. |
||||||||||||||||||||||||
| 2007 Feb 16 DRG® introduces newest CHROMagar™ media: CHROMagar™ Salmonella Plus | ||||||||||||||||||||||||
|
DRG® is pleased to launch CHROMagar's newest media, the CHROMagar™ Salmonella Plus, in a wide marketing campaign. For this purpose, we are pleased to propose an introductory offer for our new product: Buy 2 - Get 1 FREE !!! We hope to relay this special offer to our US customers in an effort to get the widest possible awareness of this new media and its advantages by a "testing-then-adopting" dynamic. We would like to bring your attention to the two new features of the CHROMagar™ Salmonella Plus: 1) It detects, in addition to the classical Salmonella strains, the Lactose positive Salmonella. This is a requirement in the ISO 6579:2003 norm. 2) It has a very nice colour contrast since the E.coli are colourless, thus making the reading of the plate much easier. Please click on this link to view the product leaflet and learn the full features of the new CHROMagar™ Salmonella Plus media. Please feel free to ask for copies of the NEW CHROMagar™ Salmonella Plus product leaflet. Requests can be made via e-mail at marketing@drg-international.com OR fax at 1-908-233-0758. * NOTE: This special offer expires April 30, 2007. |
||||||||||||||||||||||||
| 2006 Apr 28 Neonatal Screening PKU (Phenylketonuria) | ||||||||||||||||||||||||
|
Phenylalanine Phenylketonuria (PKU) is a genetic disease with autosomal recessive inheritance Phenylketonuria (PKU) is one of the most prevalent hereditary diseases in the metabolism of amino acids. It is transmitted autosomally recessive to the descendant with an incidence of approximately 1:2600 to 1:25000 dependent on the observed population group. The main cause of the disease (90 to 99% of all cases) is a decrease in or the absence of the activity of the enzyme complex Phenylalaninehydroxylase which is responsible for the transformation of the essential amino acid Phenylalanine into Tyrosine. The disease becomes apparent with mental retardation of the patient beginning in the first few weeks of life. Improper myelinization of the neurons in the brain is responsible for this development due to a change in protein metabolism. Other signs of Phenylketonuria are lack of pigmentation of the dermis and eczema-like rash due to disturbance of the synthesis of Melanin and consequent predisposition to skin diseases.
Early diagnosis of Phenylketonuria in newborns is of utmost importance because cerebral damage can be prevented by a low Phenylalanine diet. Therefore a screening test for the detection of elevated Phenylalanine concentrations in the blood needs to be made between the third and fifth day of the infant’s life. If this first reading is positive, it is followed by a confirmatory assay to detect the special mutations on chromosome 12. The DRG® Phenylalanine Neonatal Screening Assay kit is an enzymatic assay for the quantitative determination of L-Phenylalanine in human newborn blood spots. PKU Assay for 3 mm Dried Blood Spots -- Measurement at 450 nm available soon! |
||||||||||||||||||||||||
| 2006 Apr 28 New ELISA | ||||||||||||||||||||||||
|
PLGF (Placenta Growth Factor) A New Marker for Preeclampsia Angiogenesis and vascular transformation are important processes in normal development of the placenta. Abnormal angiogenesis and vascular transformation are considered to be two of the main reasons for preeclamptic pregnancies and intrauterine growth retardation. Placental Growth Factor (PLGF), a member of the VEGF family, is produced chiefly by the placenta and is a potent angiogenic factor. The corresponding receptor, the soluble fms-like tyrosine kinase-l is considered to have anti-angiogenic properties. Now, a new PLFG ELISA kit for routine diagnostics is available, which offers new possibilities in the prediction of preeclampsia. The PLGF concentration in normal pregnancies showed a steady increase with a peak at 28 to 32 weeks, and a consistent decline thereafter. The preeclamptic pregnancies, especially the early-onset forms, showed significantly lower serum concentrations without a peak.
Ready-to-use reagents |
||||||||||||||||||||||||
| 2006 Apr 28 New ELISA | ||||||||||||||||||||||||
|
PAPP-A (Ultrasensitive) The measurement of cardiac markers is essential for diagnosis, risk assessment and medical treatment of patients with acute coronary syndrome (ACS). In the last few years, increasing evidence has shown that PAPP-A, a well-known marker for first- trimester Down Syndrome screening, is increased in ACS patients, in particular in patients with unstable coronary artery plaque. Importantly, elevated PAPP-A levels were also found in ACS patients with cTnl and/or CRP-negative outcome. PAPP-A is therefore an independent marker for risk assessment and diagnosis in patients with ACS. Since the PAPP-A levels in both healthy individuals and in ACS patients are very low in comparison to PAPP-A levels in pregnant women, we have developed and evaluated a new ultrasensitive PAPP-A ELISA for the detection of elevated PAPP-A levels associated with ACS. The DRG® ultrasensitive PAPP-A ELISA is a sandwich immunoassay using a polyclonal capture antibody and a biotinylated monoclonal anti-PAPP-A antibody in combination with a streptavidin horseradish peroxidase complex as a detection system.
The diagram shows the results of a study in which DRG Instruments GmbH tested 106 ACS patients (mean 42.9 ng/ml) and 119 healthy individuals in the control group (mean 12.8 ng/ml). |
||||||||||||||||||||||||
| 2005 Feb 01 DRG® launches PLATINUM STANDARD TUMOR MARKERS | ||||||||||||||||||||||||
|
for the screening of post-treatment cancer patients Under the license of Fujirebio Diagnostics, Inc. (FDI), DRG® is pleased to introduce to its line of ELISA products, the PLATINUM STANDARD MONOCLONAL ANTIBODIES developed to detect a variety of TUMOR MARKERS. |
||||||||||||||||||||||||
| 2004 Aug 13 DRG® Novum Branch Laboratory announces new line of infectious disease Elisa diagnostics | ||||||||||||||||||||||||
|
For more information please click on Products, then DRG® Novum Branch Lab. The DRG® Group is pleased to reintroduce the former Novum Diagnostics products which were acquired by the DRG® Group earlier in 2004. We are pleased to inform you that the DRG® Novum Branch Laboratory situated in Dietzenbach, Germany remains in the original laboratory facility and all key personnel have been retained by DRG®. We look forward to your inquiries and we will be happy to service you with the usual high quality Elisa products developed, manufactured, and supplied by the DRG® Group. |
||||||||||||||||||||||||
| 2004 Apr 01 IMPORTANT CHANGES IN THE METHOD FOR SPERM ANTIBODY ELISA TESTS (EIA-1826 and EIA-4249) | ||||||||||||||||||||||||
|
DRG® would like to announce an important change in the method for Sperm Antibody ELISA . The Sperm Antibody ELISA (Catalog No. EIA-1826) is now recommended for serum samples only. However, we now introduce a new ELISA kit which is specially designed for seminal plasma samples, the Sperm Antibody ELISA test (Seminal Plasma), Catalog No. EIA-4249. Below are the specifications for the new Sperm Ab ELISA test (EIA-4249) for Seminal Plasma:
Similarly, there are some modifications in the instructions for use for EIA-1826 Sperm Ab ELISA. The main changes are:
To view the updated version of the Instructions-For-Use (IFU) for both EIA-1826 and EIA-4249, please click on EIA-1826 and EIA-4249. |
||||||||||||||||||||||||
Visit DRG® Subsidiary Website
by clicking appropriate flag
-
USA HEADQUARTERS
-
GERMANY
-
RUSSIA
-
POLAND
-
CHINA
-
CZECH REPUBLIC
Product Updates
Home » Product Updates
